MAP2K7 and malignant colon neoplasm: This finding is reminiscent of the recent report that PARPi co-opts MEK as a resistance mechanism in KRAS-mutant ovarian, lung and colon cancer [53], further underscoring the similarity between MPM and RAS-driven cancer.